Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Placebo Parallel-Controlled Clinical Study to Evaluate the Safety and Efficacy of Botulinum Toxin Type A for Injection (HengLi ®) for Prophylactic Treatment of Chronic Migraine in Adults

NCT02291380 is registered in ClinicalTrials.gov with Lanzhou Institute of Biological Products Co., Ltd as lead sponsor.

NCT NCT02291380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02291380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Placebo Parallel-Controlled Clinical Study to Evaluate the Safety and Efficacy of Botulinum Toxin Type A for Injection (HengLi ®) for Prophylactic Treatment of Chronic Migraine in Adults
Lead sponsor
Lanzhou Institute of Biological Products Co., Ltd
Phase
Phase 3
Overall status
Unknown status
Start date
September 30, 2014
Completion date
June 30, 2020
Enrollment
288 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic migraine